Results 61 to 70 of about 506,829 (351)

Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha [PDF]

Biochemistry Insights, 2008
Tumor necrosis factor-alpha (TNF-α), a member of the TNF superfamily, was the first cytokine to be evaluated for cancer biotherapy. However, the clinical use of TNF-α is severely limited by its toxicity. Currently, TNF-α is administered only through locoregional drug delivery systems such as isolated limb perfusion and isolated hepatic perfusion.
Weibo, Cai, Zachary J, Kerner, Hao, Hong, Jiangtao, Sun   +3 more
openaire   +2 more sources

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Arthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Y. Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

The Impact of Chronic Periodontitis on Mother-Infant Bonding Status in Relation to Salivary Tumor Necrosis Factor Alpha and Interleukin-6

Journal of Baghdad College of Dentistry, 2019
Background: Chronic periodontitis is a bacterial infection that result in bone destruction associated with the increasing level of salivary tumor necrosis alpha and interleukin6 that affect Mother-infant bonding status.
Liqa S Hassan, Ban S Diab
doaj   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Self‐Immolative Activatable Nanoassembly toward Immuno‐Photodynamic Therapy in TME

Advanced Functional Materials, EarlyView.
A quinone methide‐gated, self‐immolative, H2O2‐responsive nano‐photosensitizer (Pyz/PS) is developed for targeted immuno‐photodynamic therapy. Pyz/PS selectively activates within tumor microenvironments, restores photosensitizer activity, generates ROS, and depletes intracellular GSH, enhancing oxidative stress.
Jing Li, E Pang, Snehasish Debnath, Jia Hong, Aojun Qiu, Dongeun Kim, Goeun Kim, Minhuan Lan, Min‐Goo Lee, Qian‐Yong Cao, Jong Seung Kim   +10 more
wiley   +1 more source

A 3D Biofabricated Disease Model Mimicking the Brain Extracellular Matrix Suitable to Characterize Intrinsic Neuronal Network Alterations in the Presence of a Breast Tumor Disseminated to the Brain

Advanced Functional Materials, EarlyView.
A 3D disease model is developed using customized hyaluronic‐acid‐based hydrogels supplemented with extracellular matrix (ECM) proteins resembling brain ECM properties. Neurons, astrocytes, and tumor cells are used to mimic the native brain surrounding.
Esra Türker, Mateo S. Andrade Mier, Jessica Faber, Mike Friedrich, Zan Lamberger, Jeannette Weigelt, Christian Stigloher, Nicoletta Murenu, Natascha Schaefer, Jörg Tessmar, Gregor Lang, Silvia Budday, Katrin G. Heinze, Antje Appelt‐Menzel, Pamela L. Strissel, Reiner Strick, Carmen Villmann   +16 more
wiley   +1 more source

Measurement of tumor necrosis factor-&alpha;, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease

International Journal of COPD, 2008
Fanny WS Ko1, Ting-Fan Leung2, Gary WK Wong2, Jenny Ngai1, Kin W To1, Susanna Ng1, David SC Hui11Department of Medicine and Therapeutics; 2Department of Pediatrics, The Chinese University of Hong Kong, Hong KongBackground: Assessment of airway ...
Fanny WS Ko, Ting-Fan Leung, Gary WK Wong, Jenny Ngai, Kin W To, et al   +5 more
doaj  

Nilai Prognostik Tumor Necrosis Factor Alpha Demam Berdarah Dengue pada Anak

Sari Pediatri, 2016
Latar belakang. Demam berdarah dengue (DBD) adalah penyakit yang disebabkan oleh virus dengue. Patogenesisnya sampai saat ini belum jelas. Sitokin diduga berperan dalam patogenesis DBD. Prognosis sulit diramalkan. Tujuan.
Idham Jaya Ganda
doaj   +1 more source

Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis

ACG Case Reports Journal, 2017
Treatment of acute pancreatitis remains a challenge, with therapy focused on supportive care and treating the inciting etiology. Tumor necrosis factor-alpha (TNFα) inhibitors have shown promising results treating acute pancreatitis in animal models, but they have not been evaluated in human trials yet.
Werlang, Monia E., Lewis, Michele D., Bartel, Michael J.   +2 more
openaire   +2 more sources

A Smart Bio‐Battery Facilitates Diabetic Bone Defect Repair Via Inducing Macrophage Reprogramming and Synergistically Modulating Bone Remodeling Coupling

Advanced Functional Materials, EarlyView.
This research presents a novel implantable bio‐battery, GF‐OsG, tailored for diabetic bone repair. GF‐OsG generates microcurrents in high‐glucose conditions to enhance vascularization, shift macrophages to the M2 phenotype, and regulate immune responses.
Nanning Lv, Haifu Sun, Wenxiang Tang, Yonggang Li, Zhonglai Qian, Lihui Hong, Chong Chen, Hongye Li, Jiaxiang Bai, Yusen Qiao, Mingming Liu   +10 more
wiley   +1 more source